Welcome to our dedicated page for BioAtla SEC filings (Ticker: BCAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAtla, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing CAB antibody therapeutics for solid tumors. Recent Form 8-K disclosures cover financial results, investor presentation materials, cost-reduction actions, executive retention compensation, financing arrangements, license-related updates and risk-linked operating disclosures.
The filings also record capital-structure and governance matters, including shareholder votes on stock issuance and reverse split authority, Series A Junior Preferred Stock issuance and elimination, Nasdaq continued-listing proceedings, and a Delaware certificate of merger connected to a common-stock reclassification.
BioAtla Director Scott Andrew Smith received a significant equity grant on June 18, 2025, consisting of 23,500 restricted stock units (RSUs). The RSUs were granted at $0 cost and will fully vest on the earlier of June 18, 2026, or the next annual stockholder meeting, contingent on Smith's continued service.
Following this transaction, Smith's direct beneficial ownership increased to 321,550 shares. This equity award appears to be part of the company's director compensation program, aligning the director's interests with shareholders through a one-year vesting schedule.
- Transaction Type: RSU Grant (Non-derivative securities)
- Reporting Person Role: Director
- Vesting Terms: 100% after one year or next annual meeting
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)